0000000000413946

AUTHOR

M Möhler

showing 4 related works from this author

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Magenkarzinom – Was gibt’s Neues?

2011

Oncologymedicine.medical_specialtybusiness.industryInternal medicinemedicineCancerS3 leitlinieGeneral MedicineGuidelinemedicine.diseasebusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Diagnose von Intraduktal papillär-muzinöse Neoplasien (IPMN) – Bestandsaufnahme der Versorgungsrealität an einem deutschen Zentrum

2019

Ultraschall in der Medizin - European Journal of Ultrasound
researchProduct

Mehrwert von EUS gesteuerten Fein-Nadel-Biopsien (FNB) gegenüber FN-Aspiration (FNA) von unklaren Läsionen im Gastrointestinal (GI)-Trakt

2018

Interdisziplinärer Kongress | Ultraschall 2018 – 42. Dreiländertreffen SGUM | DEGUM | ÖGUM
researchProduct